Lynk Pharmaceuticals is one of biotechnology companies I've ever met, which boasts the highest R&D efficiency in novel drugs. Established in four years ago, it has four self-developed drugs entering into clinical trial stage. Moreover, its projects are worthy of credits for the reason that the ongoing pipeline combination balancing between return on investment and risk of failure is established based on unmet medical needs. Besides, Lynk has successfully out-licensed a preclinical candidate to a US company and has bought early-stage innovation of Japan’s top research institute, which embodies its excellent abilities in international business development.